Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?

Vascular Pharmacology

Volumn 47, Issue 2-3, 2007, Pages 184-188

  Madden, Brendan P ^a   Sheth, Abhijat ^a   Wilde, Mike ^a   Ong, Yee Ean ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Secondary pulmonary hypertension; Sildenafil

Indexed keywords

ANTIBIOTIC AGENT; SILDENAFIL;

ADULT; AGED; ARTHRITIS; ARTICLE; CARDIOVASCULAR FUNCTION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EXERCISE TEST; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GRAM NEGATIVE INFECTION; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SLEEP APNEA SYNDROME; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; WALKING;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; MALE; MIDDLE AGED; PIPERAZINES; PURINES; SLEEP APNEA SYNDROMES; SULFONES; TIME FACTORS; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 34547116201     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2007.06.003     Document Type: Article

References (12)

1. American Thoracic Society. ATS statement: guidelines for the six-minute walk Test. Am. J. Respir. Crit. Care Med. 166 (2002) 111-117
2. BTS Guidelines on COPD in Adults. Clinical Guideline 12. February 2004; (www.nice.org.uk/CG012 NICE guideline).
3. Ghofrani H., Wiedemann R., Rose F., Olschewski H., Schermuly R., Weissmann N., Seeger W., and Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136 (2002) 515-522
4. Gross T.J., and Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345 (2001) 517-525
5. Madden B.P., Hodson M.E., Tsang V., Radley-Smith R., Khagani A., and Yacoub M. Intermediate term result of heart lung transplant for cystic fibrosis. Lancet 339 8809 (1992) 1583-1587
6. Madden B.P., Sheth A., Ho T.B., Park J.E., and Kanagasabay R.R. Potential role for Sildenafil in the management of perioperative pulmonary hypertension and right ventricular dysfunction after cardiac surgery. BJA 93 1 (2004) 155-156
7. Madden B.P., Allenby M., Loke T.K., and Sheth A. Potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vasc. Pharmacol. 44 (2006) 372-376
8. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2 1 (2005) 20-22
9. Paulus W.J. Endothelial control of vascular and myocardial function in heart failure. Cardiovasc. Drugs Ther. 8 (1994) 437-446
10. Presberg K., and Dincer H.E. Pathophysiology of pulmonary hypertension due to lung disease. Curr. Opin. Pulm. Med. 9 (2003) 131-138
11. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr. Opin. Pulm. Med. 9 5 (2003) 426-430
12. Sheth A., Park J.E.S., Ong Y.E., Ho T.B., and Madden B.P. Early haemodynamic benefit of Sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vasc. Pharmacol. 42 (2005) 41-45